secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2026-09-10T20:13:52+00:00
Accession:  0001193125-26-387890
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell completes LYL273 manufacturing transfer to LyFE; Phase 1/2 data and FDA meeting expected 2027
--------------------------------------------------------------------------------

- Completed technology transfer of LYL273 to LyFE Manufacturing Center in Bothell, WA after FDA review of improved process and analytical methods.
- Phase 1/2 trial in relapsed/refractory metastatic colorectal cancer continues enrolling; goal to determine recommended Phase 2 dose and safety plan.
- Additional clinical data and End-of-Phase 1 meeting with FDA now expected in 2027.
- CEO Lynn Seely notes encouraging clinical activity data and activation of additional clinical sites for expansion phase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312526387890/0001193125-26-387890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312526387890/d278670d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-387890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer